Sequestration And Medicare
This article was originally published in The Pink Sheet Daily
Payments to Medicare Part D plans and Part B providers will be cut by 2%, but CMS has not yet provided details on how much it will cut reimbursement for Part B drugs.
You may also be interested in...
Biogen value-based contract with UPMC Health Plan ties payments to patient-reported outcomes for Tecfidera and Avonex. The company may seek something similar for Vumerity.
As interest in immune/inflammatory disease increases and savings achieved dip, payer focus on patient-reported outcomes for contracts reflects shift in focus, Avalere survey suggests.
ICER president Steve Pearson is ‘cautiously optimistic’ that net pricing for acute migraine treatments will align with benefits once discounts are factored in.